enGene Therapeuctics Inc Share Price Today: Live Updates & Key Insights

enGene Therapeuctics Inc share price today is $1.855, up -3.7%. The stock opened at $1.87 against the previous close of $1.89, with an intraday high of $1.87 and low of $1.81.

enGene Therapeuctics Inc Share Price Chart

enGene Therapeuctics Inc

us-stock
To Invest in {{usstockname}}
us-stock

enGene Therapeuctics Inc Share Price Performance

$1.855 -0.037(-3.7%) ENGN at 27 Jul 2026 02:51 PM Biotechnology
Lowest Today 1.81
Highest Today 1.87
Today’s Open 1.87
Prev. Close 1.89
52 Week High 12.25
52 Week Low 1.40
Day’s Range: Low 1.81 High 1.87
52-Week Range: Low 1.40 High 12.25
1 day return -
1 Week return -2.41
1 month return +4.01
3 month return -74.93
6 month return -84.07
1 year return -49.3
3 year return -83.16
5 year return -
10 year return -

enGene Therapeuctics Inc Institutional Holdings

Siren, L.L.C. 7.84

Blue Owl Capital Holdings LP 6.59

Deep Track Capital, LP 6.53

BRAIDWELL LP 3.67

Nextech Invest, Ltd. 3.47

MPM Oncology Impact Management LP 2.75

Kynam Capital Management, LP 2.03

Franklin Resources Inc 1.96

Polar Capital Holdings PLC 1.83

Balyasny Asset Management LLC 1.72

Millennium Management LLC 1.43

Omega Fund Management LLC 1.31

SR ONE CAPITAL MANAGEMENT, LP 1.12

Affinity Asset Advisors, LLC 0.91

Kennedy Capital Management Inc 0.64

Privium Fund Management B.V. 0.53

Marshall Wace Asset Management Ltd 0.51

Monashee Investment Management LLC 0.48

Birchview Capital, LP 0.37

Woodline Partners LP 0.37

Kennedy Micro Cap 0.26

Kennedy Micro Cap Opportunities 0.11

Fidelity Nasdaq Composite Index 0.06

Pleiades Small Cap Equity A 0.04

North Square Kennedy MicroCap I 0.02

JNL/DFA US Small Cap A 0.01

Northern Small Cap Core I 0.01

Dimensional US Sm Company EUR Acc 0.01

NT Quality Small Cap Core 0.00

AST Small-Cap Equity Portfolio 0.00

Dimensional US Core Eq Mkt ETF USD Acc 0.00

LO Selection The Global Balanced EUR MA 0.00

enGene Therapeuctics Inc Market Status

Strong Buy: 4

Buy: 5

Hold: 1

Sell: 0

Strong Sell: 0

enGene Therapeuctics Inc Fundamentals

Market Cap 126.61 M

PB Ratio 0.487

PE Ratio 0.0

Enterprise Value -98.17 M

Total Assets 221.47 M

Volume 665841

enGene Therapeuctics Inc Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M

Annual Profit FY25:-509000 -0.5M, FY24:null 0.0M, FY23:-175000 -0.2M

Annual Net worth FY25:117302000 117.3M, FY24:55142000 55.1M, FY23:-99917000 -99.9M

Quarterly Revenue Q2/2026:0 0.0M, Q1/2026:0 0.0M, Q4/2025:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M

Quarterly Profit Q2/2026:-180000 -0.2M, Q1/2026:-189000 -0.2M, Q4/2025:-171000 -0.2M, Q3/2025:-130000 -0.1M, Q2/2025:-106000 -0.1M

Quarterly Net worth Q2/2026:30227000 30.2M, Q1/2026:-29752000 -29.8M, Q4/2025:-37880000 -37.9M, Q3/2025:-28991000 -29.0M, Q2/2025:25815000 25.8M

About enGene Therapeuctics Inc & investment objective

Company Information enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Organisation Biotechnology

Employees 81

Industry Biotechnology

CEO Mr. Ronald H. W. Cooper

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

enGene Therapeuctics Inc FAQs

What is the share price of enGene Therapeuctics Inc today?

The current share price of enGene Therapeuctics Inc is $1.855.

Can I buy enGene Therapeuctics Inc shares in India?

Yes, Indian investors can buy enGene Therapeuctics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy enGene Therapeuctics Inc shares in India?

You can easily invest in enGene Therapeuctics Inc shares from India by:

Can I buy fractional shares of enGene Therapeuctics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of enGene Therapeuctics Inc?

enGene Therapeuctics Inc has a market cap of $126.61 M.

In which sector does enGene Therapeuctics Inc belong?

enGene Therapeuctics Inc operates in the Biotechnology sector.

What documents are required to invest in enGene Therapeuctics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of enGene Therapeuctics Inc?

The PE ratio of enGene Therapeuctics Inc is N/A and the PB ratio is 0.49.